Oncolytics Biotech Stock Today
| ONC Stock | CAD 1.33 0.04 2.92% |
Performance2 of 100
| Odds Of DistressLess than 46
|
Oncolytics Biotech is selling at 1.33 as of the 23rd of November 2024; that is 2.92 percent decrease since the beginning of the trading day. The stock's open price was 1.37. Oncolytics Biotech has 46 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Oncolytics Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. The company has 77.07 M outstanding shares of which 439.37 K shares are now shorted by private and institutional investors with about 2.2 days to cover all short positions. More on Oncolytics Biotech
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oncolytics Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncolytics Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncolytics Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Dr MBA | ||||
| Thematic Idea | IT (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | ||||
Oncolytics Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Oncolytics Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsOncolytics Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncolytics Biotech's financial leverage. It provides some insight into what part of Oncolytics Biotech's total assets is financed by creditors.
| |||||
Oncolytics Biotech (ONC) is traded on Toronto Exchange in Canada and employs 32 people. Oncolytics Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 102.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncolytics Biotech's market, we take the total number of its shares issued and multiply it by Oncolytics Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncolytics Biotech operates under Biotechnology sector and is part of Health Care industry. The entity has 77.07 M outstanding shares of which 439.37 K shares are now shorted by private and institutional investors with about 2.2 days to cover all short positions.
Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Check Oncolytics Biotech Probability Of Bankruptcy
Ownership AllocationOncolytics Biotech owns a total of 77.07 Million outstanding shares. Oncolytics Biotech holds 3.81 pct. of its outstanding shares held by insiders and 1.76 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncolytics Ownership Details
Oncolytics Biotech Risk Profiles
Although Oncolytics Biotech's alpha and beta are two of the key measurements used to evaluate Oncolytics Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.15 | |||
| Semi Deviation | 3.09 | |||
| Standard Deviation | 5.19 | |||
| Variance | 26.96 |
Oncolytics Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oncolytics Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Oncolytics Biotech Corporate Directors
| Ger Amersfoort | Independent Director | Profile | |
| William Rice | Independent Director | Profile | |
| Edwin Levy | Independent Director | Profile | |
| Linda Hohol | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.